公开(公告)号：US20140114067A1

公开(公告)日：2014-04-24

申请号：US14048979

申请日：2013-10-08

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Ae Nim PAE ,  Sun Joon MIN ,  Eun Joo ROH ,  Ha Yun YANG ,  Tae Hoon KIM ,  Beoung Gun PARK ,  Yong Seo CHO

IPC: C07D413/06 ,  C07D403/06 ,  C07D401/06 ,  C07D233/26

CPC classification number: C07D413/06 ,  C07D235/08 ,  C07D235/10 ,  C07D235/12 ,  C07D235/14 ,  C07D235/28 ,  C07D401/06 ,  C07D403/06 ,  C07D403/12

Abstract: Provided are a benzimidazole derivative modulating mitochondrial functions and having pharmaceutical activity as a neuro-protective agent, and a pharmaceutical composition including the compound as an active ingredient.

Abstract translation: 提供调节线粒体功能并具有作为神经保护剂的药物活性的苯并咪唑衍生物和包含该化合物作为活性成分的药物组合物。

公开(公告)号：US20170298011A1

公开(公告)日：2017-10-19

申请号：US15516395

申请日：2015-09-24

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Ki Duk PARK ,  ChangJoon Justin LEE ,  Dong Jin KIM ,  Ae Nim PAE ,  Hyun Ah CHOO ,  Sun Joon MIN ,  Yong Koo KANG ,  Yun Kyung KIM ,  Hyo Jung SONG ,  Ji Won CHOI ,  Min Ho NAM ,  Jun Young HEO ,  Seul Ki YEON ,  Bo Ko JANG ,  Eun Ji JU ,  Seon Mi JO ,  Jong-Hyun PARK

IPC: C07C237/06 ,  C07C231/12

Abstract: The present disclosure relates to an α-aminoamide derivative compound and a pharmaceutical composition containing the same. According to various embodiments of the present disclosure, provided is a therapeutic agent which can overcome the disadvantages of existing drugs used as a MAO-B inhibitor and, specifically, reversibly inhibits MAO-B through a non-covalent bond so as to alleviate or eliminate the side effects of the existing drugs which exhibit a therapeutic effect by irreversibly acting via a covalent bond with MAO-B. Particularly, a new compound having superior stability and efficacy compared to the existing reversible MAO-B inhibitors may be provided.

公开(公告)号：US20140206876A1

公开(公告)日：2014-07-24

申请号：US13943019

申请日：2013-07-16

Applicant: Korea Institute of Science and Technology

Inventor： Sun Joon MIN ,  Yong Seo CHO ,  Ae Nim PAE ,  Eun Jeong LIM ,  Ji Yeong KIM ,  Myung Hee SON ,  Jae Kyun LEE

IPC: C07D215/06 ,  C07D215/20 ,  C07D401/06

CPC classification number: C07D215/06 ,  C07D215/20 ,  C07D401/06

Abstract: Provided is a 2-(substituted ethynyl)quinoline derivative having an mGluR5 antagonistic activity and pharmaceutically acceptable salts thereof. The compound of the present invention can be useful as a medicament for treating and preventing mGluR5 receptor-mediated diseases such as Alzheimer's disease, senile dementia, Parkinson's disease, L-DOPA-induced dyskinesia, Huntington's chorea, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, anxiety disorder, depression, neuropathic pain, drug dependence, fragile X syndrome, autism, migraine and gastroesophageal reflux disease (GERD).

Abstract translation: 本发明提供具有mGluR5拮抗活性的2-（取代乙炔基）喹啉衍生物及其药学上可接受的盐。 本发明的化合物可用作治疗和预防mGluR5受体介导的疾病如阿尔茨海默氏病，老年性痴呆，帕金森病，L-DOPA诱导的运动障碍，亨廷顿舞蹈病，肌萎缩性侧索硬化，多发性硬化，精神分裂症 ，焦虑症，抑郁症，神经性疼痛，药物依赖，脆性X综合征，自闭症，偏头痛和胃食管反流病（GERD）。